Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)	Redeemable Convertible Preferred Stocks [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2023	$ 94,178,404	$ 2	$ 5,468,006	$ (105,094,521)	$ (99,626,513)
Beginning balance, shares at Dec. 31, 2023	24,678,355	1,690,760
Issuance of common stock in initial public offering, net of underwriting discounts, commissions and offering costs of $3,734,389		$ 3	22,025,608		22,025,611
Issuance of common stock in initial public offering, net of underwriting discounts, commissions and offering costs, shares		3,220,000
Conversion of redeemable convertible preferred stock into common stock upon closing of initial public offering	$ (94,178,404)	$ 14	94,178,390		94,178,404
Conversion of redeemable convertible preferred stock into common stock upon closing of initial public offering, shares	(24,678,355)	13,710,379
Conversion of related party convertible notes payable into common stock upon closing of initial public offering		$ 1	8,092,506		8,092,507
Conversion of related party convertible notes payable into common stock upon closing of initial public offering, shares		884,427
Reclassification of warrant liability to equity upon exchange of warrants to purchase redeemable convertible preferred stock for warrants to purchase common stock upon closing of initial public offering			485,172		485,172
Exercise of in-the-money warrants to purchase redeemable convertible preferred stock and conversion into common stock upon closing of initial public offering			238,540		238,540
Exercise of in-the-money warrants to purchase redeemable convertible preferred stock and conversion into common stock upon closing of initial public offering, shares		26,070
Stock-based compensation expense			1,995,793		1,995,793
Net loss				(27,285,328)	(27,285,328)
Ending balance, value at Dec. 31, 2024		$ 20	132,484,015	(132,379,849)	104,186
Ending balance, shares at Dec. 31, 2024		19,531,636
Issuance of shares under underwritten public offering, net of underwriter discounts and issuance costs of $1,676,036		$ 3	15,573,963		15,573,966
Issuance of shares under underwritten public offering, net of underwriter discounts and issuance costs, shares		2,464,286
Issuance of shares under June 2025 Private Placement, net of issuance costs of $73,017			4,592,462		4,592,462
Issuance of shares under June 2025 Private Placement, net of issuance costs, shares		666,497
Issuance of shares under Committed Equity Facility, net of issuance costs of $603,655			3,800,465		3,800,465
Issuance of shares under Committed Equity Facility, net of issuance costs, shares		539,967
Exercise of stock option awards			34,115		34,115
Exercise of stock option awards, shares		15,942
Issuance of vested and settled restricted stock units
Issuance of vested and settled restricted stock units, shares		26,875
Stock-based compensation expense			6,046,661		6,046,661
Net loss				(22,227,852)	(22,227,852)
Ending balance, value at Dec. 31, 2025		$ 23	$ 162,531,681	$ (154,607,701)	$ 7,924,003
Ending balance, shares at Dec. 31, 2025		23,245,203

ACTUATE THERAPEUTICS, INC. 10-K